30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

G1 Therapeutics Inc (GTHX)

Track

Stock chart
Ticker: GTHX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Perry Andrew
Chief Commercial Officer
1 sale — total 3,353 USD
Sale 5 Jul 2024
Value US$4,574,317.89 | Price 246.54 | Shares 77,747
Sale 5 Jul 2024
Value US$3,502,766.19 | Price 473.80 | Shares 82,960
Sale 5 Jul 2024
Value US$6,206.56 | Price 2.51 | Shares 2,475
Sale 5 Jul 2024
Value US$19,214.00 | Price 2.51 | Shares 7,662
Sale 5 Jul 2024
Value US$1,321.56 | Price 2.51 | Shares 527
Sale 5 Jul 2024
Value US$6,615.31 | Price 2.51 | Shares 2,638
Sale 23 May 2024
Value US$24,864.20 | Price 4.27 | Shares 5,826
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$39,033.51 | Price 4.79 | Shares 8,151
Sale 13 May 2024
Value US$178,421.11 | Price 4.79 | Shares 37,258
Proposed sale 9 Apr 2024
Value US$136,388.61 | Price 4.80 | Shares 28,393
Sale 18 Mar 2024
Value US$19,751.64 | Price 3.02 | Shares 6,547
Planned sale 12 Feb 2024
Value US$132,143.44 | Price 4.62 | Shares 28,600
Proposed sale 12 Feb 2024
Value US$132,143.44 | Price 4.62 | Shares 28,600
Proposed sale 9 Jan 2024
Value US$192,288.00 | Price 3.20 | Shares 60,000
Sale 4 Jan 2024
Value US$2,121.40 | Price 2.94 | Shares 721
Sale 4 Jan 2024
Value US$2,121.40 | Price 2.94 | Shares 721
Sale 4 Jan 2024
Value US$326.60 | Price 2.94 | Shares 111
Sale 4 Jan 2024
Value US$2,121.40 | Price 2.94 | Shares 721
Sale 3 Jan 2024
Value US$8,115.38 | Price 3.12 | Shares 2,602
Sale 3 Jan 2024
Value US$2,364.13 | Price 3.12 | Shares 758
Sale 3 Jan 2024
Value US$7,051.83 | Price 3.12 | Shares 2,261
Sale 3 Jan 2024
Value US$2,364.13 | Price 3.12 | Shares 758
Sale 3 Jan 2024
Value US$28,363.28 | Price 3.12 | Shares 9,094
Sale 3 Jan 2024
Value US$8,084.19 | Price 3.12 | Shares 2,592
Sale 3 Jan 2024
Value US$1,182.06 | Price 3.12 | Shares 379
Sale 3 Jan 2024
Value US$789.08 | Price 3.12 | Shares 253
Sale 3 Jan 2024
Value US$7,051.83 | Price 3.12 | Shares 2,261
Sale 3 Jan 2024
Value US$2,364.13 | Price 3.12 | Shares 758
Sale 3 Jan 2024
Value US$6,343.84 | Price 3.12 | Shares 2,034
Sale 3 Jan 2024
Value US$1,182.06 | Price 3.12 | Shares 379
Sale 2 Jan 2024
Value US$108,006.13 | Price 3.27 | Shares 32,983
Proposed sale 12 Dec 2023
Value US$203,916.00 | Price 3.40 | Shares 60,000
Planned sale 11 Dec 2023
Value US$49,862.88 | Price 4.02 | Shares 12,400
Planned sale 11 Dec 2023
Value US$65,659.08 | Price 3.06 | Shares 21,439
Proposed sale 11 Dec 2023
Value US$115,521.96 | Price 3.41 | Shares 33,839
Planned sale 8 Aug 2023
Value US$5,482.28 | Price 2.02 | Shares 2,714
Planned sale 8 Aug 2023
Value US$114,491.80 | Price 2.00 | Shares 57,286
Proposed sale 8 Aug 2023
Value US$119,974.08 | Price 2.00 | Shares 60,000
Planned sale 5 Jul 2023
Value US$3,339.49 | Price 2.45 | Shares 1,361
Planned sale 5 Jul 2023
Value US$3,339.49 | Price 2.45 | Shares 1,361
Planned sale 5 Jul 2023
Value US$6,671.61 | Price 2.45 | Shares 2,719
Planned sale 5 Jul 2023
Value US$871.06 | Price 2.45 | Shares 355
Sale 5 Jan 2023
Value US$3,942.07 | Price 5.41 | Shares 729
Sale 5 Jan 2023
Value US$3,942.07 | Price 5.41 | Shares 729
Sale 5 Jan 2023
Value US$3,942.07 | Price 5.41 | Shares 729
Sale 5 Jan 2023
Value US$3,942.07 | Price 5.41 | Shares 729
Sale 4 Jan 2023
Value US$31,262.39 | Price 5.58 | Shares 5,607
Sale 4 Jan 2023
Value US$4,571.99 | Price 5.58 | Shares 820
Sale 4 Jan 2023
Value US$9,138.41 | Price 5.58 | Shares 1,639
Sale 4 Jan 2023
Value US$9,138.41 | Price 5.58 | Shares 1,639
Sale 4 Jan 2023
Value US$9,138.41 | Price 5.58 | Shares 1,639
Sale 4 Jan 2023
Value US$9,138.41 | Price 5.58 | Shares 1,639
Sale 3 Jan 2023
Value US$187,452.03 | Price 5.85 | Shares 32,019
Planned sale 18 Oct 2022
Value US$175,489.50 | Price 11.70 | Shares 15,000
Planned sale 20 Sep 2022
Value US$270,044.00 | Price 13.50 | Shares 20,000
Planned sale 13 Sep 2022
Value US$282,745.80 | Price 15.71 | Shares 18,000
Planned sale 16 Aug 2022
Value US$1,010,904.00 | Price 12.64 | Shares 80,000
Sale 5 Jul 2022
Value US$3,351.13 | Price 5.17 | Shares 648
Sale 5 Jul 2022
Value US$3,351.13 | Price 5.17 | Shares 648
Sale 5 Jan 2022
Value US$15,333.62 | Price 10.61 | Shares 1,445
Sale 5 Jan 2022
Value US$15,333.62 | Price 10.61 | Shares 1,445
Sale 5 Jan 2022
Value US$15,333.62 | Price 10.61 | Shares 1,445
Sale 5 Jan 2022
Value US$15,333.62 | Price 10.61 | Shares 1,445
Sale 5 Jan 2022
Value US$15,333.62 | Price 10.61 | Shares 1,445
Sale 3 Jan 2022
Value US$355,261.72 | Price 10.41 | Shares 34,125
Planned sale 17 Jun 2021
Value US$217,728.00 | Price 21.77 | Shares 10,000
Planned sale 16 Jun 2021
Value US$217,384.00 | Price 21.74 | Shares 10,000
Planned sale 15 Jun 2021
Value US$223,909.00 | Price 22.39 | Shares 10,000
Planned sale 13 May 2021
Value US$205,413.00 | Price 20.54 | Shares 10,000
Planned sale 12 May 2021
Value US$200,691.00 | Price 20.07 | Shares 10,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-07-08 2024-07-05 S Sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
77,747 -26.6%
246.54
US$4,574,318 		77,747 -26.6% 246.54 US$4,574,318
2024-07-08 2024-07-05 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
82,960 -0.3%
473.80
US$3,502,766 		82,960 -0.3% 473.80 US$3,502,766
2024-07-08 2024-07-05 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
4,432 -3.1%
106.77
US$3,396,937 		4,432 -3.1% 106.77 US$3,396,937
2024-07-08 2024-07-05 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
7,662 -1.4%
2.51
US$19,214 		7,662 -1.4% 2.51 US$19,214
2024-07-08 2024-07-05 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
527 -0.3%
2.51
US$1,322 		527 -0.3% 2.51 US$1,322
2024-07-08 2024-07-05 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
2,638 -1.1%
2.51
US$6,615 		2,638 -1.1% 2.51 US$6,615
2024-05-24 2024-05-23 S Sale
Thomas Monica R.

Chief Legal & People Officer

Officer
5,826 -5.0%
4.27
US$24,864 		5,826 -5.0% 4.27 US$24,864
2024-05-15 2024-05-13 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
8,151 -7.9%
4.79
US$39,034 		8,151 -7.9% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
8,151 -4.8%
4.79
US$39,034 		8,151 -4.8% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
8,151 -4.8%
4.79
US$39,034 		8,151 -4.8% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
8,151 -3.7%
4.79
US$39,034 		8,151 -3.7% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
8,151 -5.1%
4.79
US$39,034 		8,151 -5.1% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
8,151 -9.4%
4.79
US$39,034 		8,151 -9.4% 4.79 US$39,034
2024-05-15 2024-05-13 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
37,258 -7.6%
4.79
US$178,421 		37,258 -7.6% 4.79 US$178,421
2024-04-09 2024-04-09 PrS Proposed sale
MARK VELLECA

Director

Non-Executive Director
28,393
4.80
US$136,389 		28,393 4.80 US$136,389
2024-03-20 2024-03-18 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
6,547 -5.0%
3.02
US$19,752 		6,547 -5.0% 3.02 US$19,752
2024-02-13 2024-02-12 PlS Planned sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
28,600 -14.4%
4.62
US$132,143 		28,600 -14.4% 4.62 US$132,143
2024-02-12 2024-02-12 PrS Proposed sale
2.9
RAJESH MALIK

Officer

Officer
28,600
4.62
US$132,143 		28,600 4.62 US$132,143
2024-01-09 2024-01-09 PrS Proposed sale
MARK VELLECA

Director

Non-Executive Director
60,000
3.20
US$192,288 		60,000 3.20 US$192,288
2024-01-08 2024-01-04 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
721 -0.6%
2.94
US$2,121 		721 -0.6% 2.94 US$2,121
2024-01-08 2024-01-04 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
721 -0.7%
2.94
US$2,121 		721 -0.7% 2.94 US$2,121
2024-01-08 2024-01-04 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
111 -0.1%
2.94
US$327 		111 -0.1% 2.94 US$327
2024-01-08 2024-01-04 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
721 -0.4%
2.94
US$2,121 		721 -0.4% 2.94 US$2,121
2024-01-08 2024-01-03 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
2,602 -2.1%
3.12
US$8,115 		2,602 -2.1% 3.12 US$8,115
2024-01-08 2024-01-03 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
758 -0.6%
3.12
US$2,364 		758 -0.6% 3.12 US$2,364
2024-01-08 2024-01-03 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
2,261 -2.1%
3.12
US$7,052 		2,261 -2.1% 3.12 US$7,052
2024-01-08 2024-01-03 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
758 -0.7%
3.12
US$2,364 		758 -0.7% 3.12 US$2,364
2024-01-08 2024-01-03 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
9,094 -1.8%
3.12
US$28,363 		9,094 -1.8% 3.12 US$28,363
2024-01-08 2024-01-03 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
2,592 -0.5%
3.12
US$8,084 		2,592 -0.5% 3.12 US$8,084
2024-01-08 2024-01-03 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
379 -0.3%
3.12
US$1,182 		379 -0.3% 3.12 US$1,182
2024-01-08 2024-01-03 S Sale
2.2
Umstead John W. V

Chief Financial Officer

Officer
253 -0.2%
3.12
US$789 		253 -0.2% 3.12 US$789
2024-01-08 2024-01-03 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
2,261 -1.3%
3.12
US$7,052 		2,261 -1.3% 3.12 US$7,052
2024-01-08 2024-01-03 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
758 -0.4%
3.12
US$2,364 		758 -0.4% 3.12 US$2,364
2024-01-08 2024-01-03 S Sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
2,034 -2.3%
3.12
US$6,344 		2,034 -2.3% 3.12 US$6,344
2024-01-08 2024-01-03 S Sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
379 -0.4%
3.12
US$1,182 		379 -0.4% 3.12 US$1,182
2024-01-02 2024-01-02 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
32,983 -7.6%
3.27
US$108,006 		32,983 -7.6% 3.27 US$108,006
2023-12-12 2023-12-12 PrS Proposed sale
MARK VELLECA

Director

Non-Executive Director
60,000
3.40
US$203,916 		60,000 3.40 US$203,916
2023-12-13 2023-12-11 PlS Planned sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
12,400 -8.3%
4.02
US$49,863 		12,400 -8.3% 4.02 US$49,863
2023-12-13 2023-12-11 PlS Planned sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
21,439 -13.6%
3.06
US$65,659 		21,439 -13.6% 3.06 US$65,659
2023-12-11 2023-12-11 PrS Proposed sale
2.9
RAJESH MALIK

Officer

Officer
33,839
3.41
US$115,522 		33,839 3.41 US$115,522
2023-08-10 2023-08-08 PlS Planned sale
Velleca Mark A.
Non-Executive Director
2,714 -2.3%
2.02
US$5,482 		2,714 -2.3% 2.02 US$5,482
2023-08-10 2023-08-08 PlS Planned sale
Velleca Mark A.
Non-Executive Director
57,286 -33.1%
2.00
US$114,492 		57,286 -33.1% 2.00 US$114,492
2023-08-08 2023-08-08 PrS Proposed sale
MARK VELLECA

Director

Non-Executive Director
60,000
2.00
US$119,974 		60,000 2.00 US$119,974
2023-07-07 2023-07-05 PlS Planned sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
1,361 -1.0%
2.45
US$3,339 		1,361 -1.0% 2.45 US$3,339
2023-07-07 2023-07-05 PlS Planned sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
1,361 -1.9%
2.45
US$3,339 		1,361 -1.9% 2.45 US$3,339
2023-07-07 2023-07-05 PlS Planned sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
2,719 -0.6%
2.45
US$6,672 		2,719 -0.6% 2.45 US$6,672
2023-07-07 2023-07-05 PlS Planned sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
355 -0.6%
2.45
US$871 		355 -0.6% 2.45 US$871
2023-01-05 2023-01-05 S Sale
3.2
Moses Jennifer K.

CFO

Officer
729 -1.2%
5.41
US$3,942 		729 -1.2% 5.41 US$3,942
2023-01-05 2023-01-05 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
729 -2.0%
5.41
US$3,942 		729 -2.0% 5.41 US$3,942
2023-01-05 2023-01-05 S Sale
2.1
Hanson James S.

General Counsel

Officer
729 -1.7%
5.41
US$3,942 		729 -1.7% 5.41 US$3,942
2023-01-05 2023-01-05 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
729 -0.7%
5.41
US$3,942 		729 -0.7% 5.41 US$3,942
2023-01-05 2023-01-04 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
5,607 -2.0%
5.58
US$31,262 		5,607 -2.0% 5.58 US$31,262
2023-01-05 2023-01-04 S Sale
2.3
Perry Andrew

Chief Commercial Officer

Officer
820 -3.7%
5.58
US$4,572 		820 -3.7% 5.58 US$4,572
2023-01-05 2023-01-04 S Sale
3.2
Moses Jennifer K.

CFO

Officer
1,639 -2.7%
5.58
US$9,138 		1,639 -2.7% 5.58 US$9,138
2023-01-05 2023-01-04 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
1,639 -4.2%
5.58
US$9,138 		1,639 -4.2% 5.58 US$9,138
2023-01-05 2023-01-04 S Sale
2.1
Hanson James S.

General Counsel

Officer
1,639 -3.8%
5.58
US$9,138 		1,639 -3.8% 5.58 US$9,138
2023-01-05 2023-01-04 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
1,639 -1.6%
5.58
US$9,138 		1,639 -1.6% 5.58 US$9,138
2023-01-05 2023-01-03 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
32,019 -10.2%
5.85
US$187,452 		32,019 -10.2% 5.85 US$187,452
2022-10-20 2022-10-18 PlS Planned sale
Velleca Mark A.
Non-Executive Director
15,000 -11.5%
11.70
US$175,490 		15,000 -11.5% 11.70 US$175,490
2022-09-22 2022-09-20 PlS Planned sale
Velleca Mark A.
Non-Executive Director
20,000 -14.7%
13.50
US$270,044 		20,000 -14.7% 13.50 US$270,044
2022-09-16 2022-09-13 PlS Planned sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
18,000 -19.7%
15.71
US$282,746 		18,000 -19.7% 15.71 US$282,746
2022-08-18 2022-08-16 PlS Planned sale
Velleca Mark A.
Non-Executive Director
80,000 -40.8%
12.64
US$1,010,904 		80,000 -40.8% 12.64 US$1,010,904
2022-07-06 2022-07-05 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
648 -0.9%
5.17
US$3,351 		648 -0.9% 5.17 US$3,351
2022-07-06 2022-07-05 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
648 -3.0%
5.17
US$3,351 		648 -3.0% 5.17 US$3,351
2022-01-05 2022-01-05 S Sale
2.5
MURDOCK TERRY L

Chief Operating Officer

Officer
1,445 -6.3%
10.61
US$15,334 		1,445 -6.3% 10.61 US$15,334
2022-01-05 2022-01-05 S Sale
2.1
Hanson James S.

General Counsel

Officer
1,445 -5.4%
10.61
US$15,334 		1,445 -5.4% 10.61 US$15,334
2022-01-05 2022-01-05 S Sale
2.4
Avagliano Mark

Chief Business Officer

Officer
1,445 -6.3%
10.61
US$15,334 		1,445 -6.3% 10.61 US$15,334
2022-01-05 2022-01-05 S Sale
2.9
Malik Rajesh

Chief Medical Officer

Officer
1,445 -2.2%
10.61
US$15,334 		1,445 -2.2% 10.61 US$15,334
2022-01-05 2022-01-05 S Sale
3.2
Moses Jennifer K.

CFO

Officer
1,445 -3.9%
10.61
US$15,334 		1,445 -3.9% 10.61 US$15,334
2022-01-05 2022-01-03 S Sale
2.2
Bailey John E. (Jack) Jr.

President and CEO

Executive Director
34,125 -12.8%
10.41
US$355,262 		34,125 -12.8% 10.41 US$355,262
2021-06-17 2021-06-17 PlS Planned sale
Velleca Mark A.
Non-Executive Director
10,000 -14.1%
21.77
US$217,728 		10,000 -14.1% 21.77 US$217,728
2021-06-17 2021-06-16 PlS Planned sale
Velleca Mark A.
Non-Executive Director
10,000 -14.1%
21.74
US$217,384 		10,000 -14.1% 21.74 US$217,384
2021-06-17 2021-06-15 PlS Planned sale
Velleca Mark A.
Non-Executive Director
10,000 -14.1%
22.39
US$223,909 		10,000 -14.1% 22.39 US$223,909
2021-05-13 2021-05-13 PlS Planned sale
Velleca Mark A.
Non-Executive Director
10,000 -19.6%
20.54
US$205,413 		10,000 -19.6% 20.54 US$205,413
2021-05-13 2021-05-12 PlS Planned sale
Velleca Mark A.
Non-Executive Director
10,000 -19.6%
20.07
US$200,691 		10,000 -19.6% 20.07 US$200,691
Explore more

More insider trading research around G1 Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America